biologic

Adstiladrin

nadofaragene firadenovec-vncg

Loss of exclusivityDecember 2034FDA regulatory exclusivity expiry

CompanyFerring Pharmaceuticals A/S

Drug detail

Brand name	Adstiladrin
Active ingredient	nadofaragene firadenovec-vncg
Strength	3x10^11 viral particles (vp)/mL
Dosage form	For Suspension
Route	Intravesical
Modality	Biologic
FDA approval	December 2022
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.